Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFMW) Net Margin (2018 - 2025)

Historic Net Margin for Sunshine Biopharma (SBFMW) over the last 8 years, with Q3 2025 value amounting to 3.14%.

  • Sunshine Biopharma's Net Margin rose 173400.0% to 3.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.06%, marking a year-over-year increase of 6600.0%. This contributed to the annual value of 14.72% for FY2024, which is 39800.0% up from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Net Margin is 3.14%, which was up 173400.0% from 31.36% recorded in Q2 2025.
  • Sunshine Biopharma's Net Margin's 5-year high stood at 783.75% during Q4 2021, with a 5-year trough of 15440.43% in Q1 2021.
  • For the 5-year period, Sunshine Biopharma's Net Margin averaged around 1651.22%, with its median value being 22.49% (2024).
  • Within the past 5 years, the most significant YoY rise in Sunshine Biopharma's Net Margin was 144324500bps (2022), while the steepest drop was -13805400bps (2022).
  • Over the past 5 years, Sunshine Biopharma's Net Margin (Quarter) stood at 783.75% in 2021, then tumbled by -176bps to 596.78% in 2022, then soared by 97bps to 16.28% in 2023, then tumbled by -38bps to 22.49% in 2024, then surged by 114bps to 3.14% in 2025.
  • Its last three reported values are 3.14% in Q3 2025, 31.36% for Q2 2025, and 13.25% during Q1 2025.